Dawn Hershman, MD, MS, medical oncologist, Columbia University Medical Center, discusses how name brands and generic brands affect drug adherence in patients with breast cancer.
Dawn Hershman, MD, MS, medical oncologist, Columbia University Medical Center, discusses how name brands and generic brands affect drug adherence in patients with breast cancer.
At the 2013 San Antonio Breast Cancer Symposium, Hershman presented a study that compared the use of aromatase inhibitor (AI) use before and after the introduction of generics.
Hershman says the study found that discontinuation rates were higher in patients on brand name AIs compared to generic names. The study also found that patients that have copayments greater than or equal to $20 per month were twice as likely of discontinuing their treatment compared to those who were paying $10 per month or less.
Hershman says income level also plays a role in adherence. The study found that those who had incomes greater than $100,000/year were significantly more likely to adhere to their hormonal therapy than those whose incomes were less than that.
The generic AIs cost about $110 per month while brand name AIs cost $300 per month, Hershman says, with some newer oral agents costing up to $9,000 per month. Since a quarter of the new drugs being developed are oral, Hershman says it is important to think about the price of these agents as well as their efficacy.
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
April 25th 2024Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.